Edwards Lifesciences Corporation

EW Healthcare Medical Devices

Edwards Lifesciences Corporation’s revenue for fiscal 2025 (year ended December 2025) was $6.1 billion, up 11.5% from fiscal 2024.

Revenue
+10.5%
EPS
+6.00%
Free cash flow
−1.84%
Total debt
+0.10%

Quarter to September 2026, against a year earlier

101.66 0.84 +0.83%
Market cap
$58.1B
P/E
56.7×
Fwd P/E
36.5×
Dividend yield
—
F-score
5/9
Altman Z
11.54
Beneish M
−2.48
Dividend safety
n/a

Edwards Lifesciences Corporation (EW) Revenue

Alert me on Revenue

Edwards Lifesciences Corporation's revenue for fiscal 2025 was $6.1B, up 11.5% from $5.4B in fiscal 2024. Over the twelve months to 30 September 2026 it was $6.7B. Over the past ten years it has ranged from $2.5B (fiscal 2015) to $6.1B (fiscal 2025) — the current reading is the highest in ten years. Revenue has risen for 3 consecutive fiscal years. Edwards Lifesciences Corporation ranks 9th of 140 Medical Devices companies by revenue.

Revenue, annual

Embed this chart

Annual newest first

Period Revenue Change
FY2025 $6.1B 11.55%
FY2024 $5.4B 8.57%
FY2023 $5.0B 12.23%
FY2022 $4.5B (14.69%)
FY2021 $5.2B 19.29%
FY2020 $4.4B 0.88%
FY2019 $4.3B 16.79%
FY2018 $3.7B 8.37%
FY2017 $3.4B 15.91%
FY2016 $3.0B 18.85%

Quarterly newest first

Period Revenue Change
Sep 2026 $1.7B (1.46%)
Jun 2026 $1.7B 5.60%
Mar 2026 $1.6B 5.03%
Dec 2025 $1.6B 1.06%
43 more quarters

Against its own ten years

Low $2.5B High $6.1B
Ten-year median $4.4B
Current reading's percentile 100

Revenue against peers

What Revenue is

Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.

Reported line item

The full definition of Revenue →

More on EW